

CHARLES UNIVERSITY IN PRAGUE

FACULTY OF MEDICINE IN HRADEC KRÁLOVÉ



**EXPERIMENTAL USE OF SELECTED CHOLESTEROL-
LOWERING DRUGS AS POTENTIAL CANDIDATES
IN MODIFICATION OF THE PATHOPHYSIOLOGY
OF ALZHEIMER'S DISEASE**

LÚBICA CIBIČKOVÁ

**DOCTORAL DISSERTATION
(SHORT REPORT)**

STUDY PROGRAM INTERNAL MEDICINE

HRADEC KRÁLOVÉ

2008

This dissertation thesis has been accomplished during combined study program Internal Medicine in fulfillment of requirements for a Ph.D. degree at the Academic Department of Medicine, Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic.

CANDIDATE: MUDr. Lubica Cibičková

Academic Department of Medicine, Faculty of Medicine in Hradec Králové,
Charles University in Prague AND 2nd Department of Medicine, University Hospital
in Hradec Králové

ACADEMIC ADVISOR: Prof. MUDr. Jaroslav Malý, CSc.

Academic Department of Medicine, Faculty of Medicine in Hradec Králové,
Charles University in Prague AND 2nd Department of Medicine, University Hospital
in Hradec Králové

ADVISOR – SPECIALIST: Prof. MUDr. Vladimír Palička, CSc., Dr. h. c.

Institute of Clinical Biochemistry and Diagnostics,
University Hospital in Hradec Králové

OPPONENTS:

doc. MUDr. Pavol Hlúbik, CSc.

Department of Military Hygiene
University of Defence, Faculty of Military Health Sciences, Hradec Králové

Prof. MUDr. Antonín Jabor, CSc.

Department of laboratory methods
Institute of clinical and experimental medicine, Praha

This study was partially supported by a Research Project of the Czech Ministry of Health (MZO 00179906), a Research Project of Ministry of Health IGA MZČR č. NR7935-3/2004 and also by an internal grant of Faculty of Medicine in Hradec Králové, Charles University in Prague (no number).

The original thesis will be available for reference at the Dean's office, Faculty of Medicine in Hradec Králové, Charles University in Prague, Šimkova 870, 500 38 Hradec Králové (tel. 495 816 131).

Prof. MUDr. Jan Bureš, CSc., the Chairperson of the Committee for defending the dissertation theses in the postgraduate study program Internal Medicine.

CONTENTS

1. SUMMARY	4
2. SOUHRN V ČEŠTINĚ	4
3. ABBREVIATIONS	5
4. INTRODUCTION	5
5. AIMS	6
6. MATERIALS AND METHODS	6
7. RESULTS	8
7.1. Levels of sterols in plasma and brain	
7.2. Cholesterol synthesis rate and HMG-CoA reductase expression in the brain	
7.3. Influence on cholinesterases	
7.3.1. AChE and BuChE in blood	
7.3.2. Effect on AChE in the brain	
7.4. Concentration of amyloid beta in the brain	
8. DISCUSSION	11
8.1. Effects of statins	
8.1.1. Biomarkers of cholesterol synthesis in the brain	
8.1.2. Influence on cholesterol synthesis	
8.1.3. Cholesterol synthesis in various parts of CNS	
8.1.4. Influence on acetylcholinesterase and amyloid beta	
8.2. Effects of alendronate	
8.3 Effects of high-cholesterol feeding	
9. CONCLUSIONS	15
10. REFERENCES	16
11. LIST OF AUTHOR'S PUBLICATIONS	20

1. SUMMARY

Rationale: The current standard treatment of Alzheimer's disease (AD) is represented by acetylcholinesterase (AChE) inhibitors. In the pathogenesis of AD, cholesterol is directly involved. Its blood and brain levels positively correlate with amyloid β (A β) - a peptide characteristic for AD and capable of increasing AChE activity. Based on these data, we may suppose that cholesterol-lowering medication such as statins and alendronate might confer protection against dementia, probably via modulation of cholesterol synthesis in the brain. The aim of the present studies was to investigate possible influence of two lipophilic statins (simvastatin and atorvastatin) and alendronate on cholesterol synthesis in selected parts of the rat central nervous system (CNS) and other parameters relevant to Alzheimer's disease pathophysiology.

Methods: We have performed 3 similar experiments on awaked rats that were administered simvastatin, atorvastatin, alendronate or aqua. At the conclusion of experiments, blood and brain parts were isolated and analyzed for cholesterol, lathosterol, hydroxymethylglutaryl-coenzyme A reductase protein, acetylcholinesterase activity, amyloid beta (40 and 42) and cholesterol synthesis rate.

Results: All drugs at higher doses were able to lower cholesterol in the plasma, but none elicited an effect on total brain cholesterol. Significant reductions of lathosterol and cholesterol synthesis rate were observed after simvastatin- and atorvastatin- treatment, whereas amyloid beta and hydroxymethylglutaryl-coenzyme A reductase levels remained unaffected. Both statins elicited comparable effects on cholesterol synthesis rate irrespective of the examined brain part. In alendronate group, the experiments brought inconsistent results concerning its influence on brain cholesterol synthesis. Both simvastatin and alendronate inhibited acetylcholinesterase activity in frontal cortex.

Conclusions: Our studies bring additional evidence of the role of statins in the brain cholesterol synthesis and are the first to show an influence of statins and alendronate on AChE activity in the rat brain. However, our data question the relationship between amyloid beta, acetylcholinesterase activity and cholesterol synthesis. For comparison of the effects of statins in selected parts of the brain, the deuterium technique was utilised for the first time.

2. SOURHN V ČEŠTINĚ

Úvod: Současný standard v terapii Alzheimerovy demence (AD) představují inhibitory acetylcholinesterázy (AChE). V patogenezi AD sehrává svou roli cholesterol, jehož hladiny v krvi a mozku pozitivně korelují s amyloidem β (A β) – proteinem charakteristickým pro AD a schopným zvyšovat aktivitu AChE. Na základě uvedených dat jsme předpokládali, že léky zasahující do biosyntézy cholesterolu (jako jsou statiny a alendronát) by mohly chránit proti demenci, pravděpodobně modulací syntézy cholesterolu v mozku. Cílem našich studií bylo zjistit možný vliv dvou lipofilních statinů (simvastatinu a atorvastatinu) a alendronátu na syntézu cholesterolu ve vybraných částech centrálního nervového systému (CNS) potkana a také na další parametry se vztahem k patofyziologii AD (A β a aktivita AChE).

Metodika: Realizovali jsme 3 obdobné experimenty. V principu jsme potkanům vždy podávali simvastatin, atorvastatin, alendronát (v různém dávkování) či vodu. Následně byla izolována krev a části mozku ke stanovení hladiny cholesterolu, lathosterolu, proteinu hydroxymethylglutaryl-koenzym A reduktázy, aktivity AChE, množství amyloidu beta (40 a 42) a rychlosti syntézy cholesterolu (pomocí metodiky s deuterium oxidem, který byl potkanům podáván vždy od druhého dne experimentu).

Výsledky: Podávané léky byly při delším podávání schopny snížit hladinu cholesterolu v plazmě, aniž by ovlivnily celkový cholesterol v mozku. Signifikantního snížení syntézy cholesterolu (hodnoceno dle poklesu lathosterolu a rychlosti syntézy cholesterolu s použitím metodiky s deuterium oxidem) bylo dosaženo po podávání jak simvastatinu, tak atorvastatinu, přičemž jejich efekt byl závislý na podané dávce. Oba statiny vykazovaly srovnatelný vliv na rychlosť syntézy cholesterolu ve všech vyšetřených částech mozku. Neprokázali jsme předpokládanou up-regulaci proteinu hydroxymethylglutaryl-koenzym A reduktázy. Také amyloid beta zůstal nezměněn. Simvastatin i alendronát inhibovaly aktivitu AChE ve frontálním kortexu. Nejednotných výsledků při studiu vlivu na syntézu cholesterolu v mozku bylo dosaženo ve skupinách s alendronátem.

Závěry: Naše studie přináší potvrzení vlivu statinů na syntézu cholesterolu v mozku (stanoveno zavedenou metodou s deuterium oxidem), přičemž jsme nově poukázali na závislost efektu na dávce a stanovovali jsme syntézu cholesterolu v různých částech CNS. Tím, že po statinech nedošlo ke změně celkového cholesterolu v mozku, jsme potvrdili schopnost mozku potkana zachovávat stabilní hladinu cholesterolu. Ve sledovaných parametrech jsme neprokázali rozdíl v účinku atorvastatinu a simvastatinu. Naše výsledky ukazují na vliv statinů a alendronátu na aktivitu AChE v mozku potkanů. Nicméně jsme zpochybnili vztah mezi amyloidem beta, aktivitou AChE a syntézou cholesterolu.

3. ABBREVIATIONS

AD - Alzheimer's disease;

ApoE - Apolipoprotein E;

APP - amyloid precursor protein,

APPs - soluble amyloid precursor protein;

A β - amyloid β -peptide;

AChE - acetylcholinesterase;

BuChE - butyrylcholinesterase;

BBB - blood-brain barrier;

CNS - central nervous system;

FSR - fraction synthesis rate;

HMG CoA -3-hydroxy-3-methylglutaryl coenzyme A;

N-BPs - nitrogen-containing bisphosphonates


4. INTRODUCTION

Alzheimer's disease (AD) is a neurodegenerative disorder with progressive cognitive impairment, personality changes and memory deficits largely attributable to deficiency in cholinergic neurotransmission. Post mortem, the unit is histopathologically characterized by an abnormal brain accumulation of amyloid β -peptide (A β). Current therapeutic strategies for AD focus on cognitive deficit alleviation via direct AChE inhibition (Jiráč, Koukolík 2004). Even though traditional medications like donepezil, rivastigmin or galantamin are at present a "gold standard" in this aspect, they are indicated as symptomatic drugs, may be less tolerable and representing a considerable financial burden. Questions arise, if present evidence points to any alternative/additional therapeutic approach that might intervene in the pathogenesis of the disease and concurrently enhance tolerability and/or reduce costs associated with the treatment of AD.

As alternatives to reduce symptoms of AD and slow the progression of the disease, several different classes of medicaments have been suggested e.g. A β vaccination, metal

chelators, anti-inflammatory drugs and cholesterol-lowering drugs. Some, but not all (Rea et al 2005; Zandi et al 2005) of recent epidemiological reports indicate, that cholesterol-lowering medicine such as statins might confer protection against dementia (Rockwood et al 2002; Zamrini et al 2004). The idea of utilizing cholesterol-modifying agents comes from experimental studies indicating a significant role of cholesterol in the pathophysiology of AD. Higher serum levels of cholesterol elevate A β and facilitate its deposition into plaques, which are of importance for the development of the disease (Sparks 1996). In addition, cholesterol inhibits α -secretase and hence hinders the production of neuroprotective soluble amyloid precursor protein (APPs) (Bergmann 2000). Moreover, A β has recently been documented to increase acetylcholinesterase (AChE) activity in vitro (Hu et al. 2003) (Figure 1). However, the exact mechanism of their action on AD has not been clarified yet.

Figure 1: Relationship between cholesterol, A β and AChE



5. AIMS OF THE STUDY

Based on the published data, I have decided to examine selected cholesterol-lowering drugs as potential candidates in modification of the pathophysiology of Alzheimer's dementia. I tested the hypothesis, that cholesterol-lowering drugs have an influence on cholesterol metabolism, cholinesterase activities and A β in the rat brain. For this purpose I utilized selected representatives from two drug groups - statins (simvastatin and atorvastatin) and bisphosphonates (alendronate). I have realized 3 experiments and its results are summarized in 4 articles as follows:

STUDY I. Cibickova Lubica, Palicka Vladimir, Cibicek Norbert, Cermakova Eva, Micuda Stanislav, Bartosova Lucie, Jun Daniel: **Differential effects of statins and alendronate on cholinesterases in serum and brain of rats.** Physiol Res 2007;56(6):765-770.

STUDY II A. Cibickova Lubica, Hyspler Radomir, Ticha Alena, Cibicek Norbert, Palicka Vladimir, Cermakova Eva, Zadak Zdenek: **Cholesterol synthesis in central nervous system of rat is affected by simvastatin as well as by atorvastatin.** Die Pharmazie 2008;63:819-22.

STUDY II B. Cibickova Lubica, Palicka Vladimir, Hyspler Radomir, Cibicek Norbert, Cermakova Eva: **Alendronate lowers cholesterol biosynthesis in the central nervous system of rats – a preliminary study.** Physiol Res 2009;58(3). In print.

STUDY III. Cibickova Lubica, Hyspler Radomir, Micuda Stanislav, Cibicek Norbert, Zivna Helena, Jun Daniel, Ticha Alena, Palicka Vladimir: **The influence of simvastatin, atorvastatin and high cholesterol diet on acetylcholinesterase activity, amyloid beta and cholesterol synthesis in rat brain.** Steroids 2009;74:13-19. In print.

6. MATERIAL AND METHODS

Drugs were administered by oral route to adult male rats of Wistar strain for 7 days (*Study I*) or 9 days (*Study II*) or 15 days (*Study III*). The animals were randomly divided into four groups, eight subjects in each. The first (sham) group served as control and received vehicle (water) only, the second group was administered atorvastatin (50 mg/kg), the third ingested simvastatin (50 mg/kg) and the fourth was exposed to alendronate (3 mg/kg). On the last day of experiment, 1 h after the last drug application (respecting c_{max}), animals were sacrificed by exsanguination, the brains were exteriorized and the studied brain tissues (basal ganglia, septum, frontal cortex and hippocampus) isolated.

Study II was similar to the first. There were only some differences: Tap water was provided ad libitum until the second day of experiment. The second day rats received a loading dose of deuterated water (35 mL/kg 99% enriched $^2\text{H}_2\text{O}$) and then had free access to drinking water enriched with 10% $^2\text{H}_2\text{O}$ (Diraison et al. 1996). The dosage of statins was lowered: atorvastatin (10 mg/kg) and simvastatin (10 mg/kg). The brains were not divided on four parts, but small samples from the basal ganglia, frontal lobe, hippocampus and spinal cord were isolated.

Study III was similar to the second with these differences: Animals were randomly divided into 8 groups, 6 subjects in each. The first (sham) group received the vehicle only (aqua pro injectione), the second was administered simvastatin (10mg/kg b.wt.), the third ingested atorvastatin (10 mg/kg b.wt.), the forth simvastatin (20 mg/kg b.wt), the fifth atorvastatin (20 mg/kg b.wt.), the sixth alendronate (3 mg/kg b.wt.) and the seventh also alendronate (6 mg/kg b.wt.). The last group received only aqua pro injectione, but was fed with a cholesterol-enriched diet (2% cholesterol).

For determination of cholesterol in the blood, plasma samples were analyzed using a routine analyzer Modular Roche.

To measure the activities of cholinesterases, the samples of individual brain parts were homogenized in distilled water using a homogenizer, erythrocytes were obtained from plasma by centrifugation. The activities of AChE and BuChE were determined using a modified method of Ellman et al. (1961).

To measure brain cholesterol synthesis rate, brain tissue was homogenized and extracted according the method of Bligh and Dyer (Bligh and Dyer, 1959). Tissue concentrations of cholesterol and lathosterol were determined using GC 8000 system equipped with a flame ionisation detector. The compounds of interest were quantified using internal standard method (alpha-cholestane for cholesterol and stigmastanol for lathosterol). Results are expressed as molar concentration per gram of wet tissue. Analysis of cholesterol synthesis rate was performed on GC-MS system (operating in electron ionization mode). The ions m/z 368.6, 369.6 and 370.6 were recorded, isotope excess and fractional synthesis rate were calculated according to Diraison (Diraison et al. 1997).

The protein expression of HMG-CoA reductase in the brain was performed by immunoblot analysis.

For determination of A β 1-40 and A β 1-42 in the brain, the samples were prepared according to Borchelt et al. (Borchelt et al. 1996). The analyses were performed using commercially available ELISA Kits (Human/Rat β Amyloid (40) ELISA Kit Wako II and Human/Rat β Amyloid (42) ELISA Kit Wako, High-Sensitive, Wako Chemicals GmbH, Germany) in compliance with the manufacturer's instructions.

The data were processed by the programs NCSS 2004 and Statistica. For statistical evaluation, Analysis Of Variance with *post hoc* Fisher's LSD Multiple-Comparison Test (between-group comparisons), Kruskal-Wallis Test and unpaired t-tests were applied. The chosen level of significance was $\alpha=0.05$.

7. RESULTS

7.1. Levels of sterols in plasma and the brain

We investigated plasma levels of cholesterol in *Study II* and *III*, not in *Study I*. In *Study IIa* treatment neither with simvastatin (10 mg/kg) nor with atorvastatin (10 mg/kg) for 9 days produced any decrease in plasma cholesterol ($p=0.31$) (*Table 1*).

Table 1: Cholesterol (mmol/l) in plasma, results are expressed as median; minimum - maximum

	Plasma
Control group	1,235; 0,98 – 2,50
Atorvastatin group	1,690; 1,20 – 2,35
Simvastatin group	1,625; 1,05 – 1,93

Also treatment with alendronate for 9 days did not produce any change in plasma cholesterol (1.37, 1.02–2.86 for alendronate vs. 1.24, 0.98–2.50 for controls; $p=0.44$, results are expressed as median, minimum–maximum).

In *Study III*, both simvastatin and atorvastatin at higher dose (20 mg/kg) and longer duration of treatment (15 days) influenced plasma and brain sterols. The mean brain cholesterol level was not different in any group compared to controls ($P = 0.16$) (*Table 2*).

Table 2: Concentrations of plasma and brain sterols in rats treated with simvastatin, atorvastatin, or alendronate or fed with a high cholesterol or normal chow (control)

	Aqua	Si – 10	At – 10	Si – 20	At – 20	AI – 3	AI – 6	Chol
Plasma cholesterol (mmol/l)	1.66 ± 0.06	1.66 ± 0.09	1.28 ± 0.81**	1.21 ± 0.06***	1.33 ± 0.11*	1.36 ± 0.10*	1.62 ± 0.10	1.94 ± 0.15
Brain cholesterol (mg/g)	55.42 ± 2.91	52.05 ± 2.25	51.92 ± 6.01	61.12 ± 4.82	62.96 ± 3.14	51.02 ± 1.52	57.25 ± 3.02	52.17 ± 1.10
Brain Lathosterol (µg/g)	73.2 ± 2.17	61.15 ± 2.02**	64.1 ± 5.78	59.65 ± 2.83**	64.78 ± 1.98*	64.2 ± 2.92*	78.17 ± 4.77	78.55 ± 3.00
Brain lathosterol /brain cholesterol (%)	1.34 ± 0.07	1.19 ± 0.06	1.26 ± 0.08	0.99 ± 0.03***	1.04 ± 0.04**	1.27 ± 0.05	1.37 ± 0.03	1.51 ± 0.37*

Data are expressed as means \pm SEM; * significantly different from Aqua $p<0.05$; ** significantly different from Aqua $p<0.01$; *** significantly different from Aqua $p<0.001$

7.2. Cholesterol synthesis rate and HMG-CoA reductase expression in brain


Brain cholesterol synthesis in the control (sham) group was compared with those measured in the atorvastatin, simvastatin and alendronate groups. Treatment with all three drugs, for the dose and time investigated, significantly decreased cholesterol synthesis in all investigated CNS parts (basal ganglia, hippocampus, frontal lobe and spinal cord) in *Study II* (*Table 3*) and similarly in the brain hemisphere homogenate in *Study III* (*Figure 1*). The higher dose of statins elicited a greater lowering of FSR than the lower dose, 77 % for simvastatin ($P < 0.001$) and also 77 % for atorvastatin ($P < 0.01$). The same dose-dependent effect was

observed on the brain lathosterol/ cholesterol ratio (see *Table 2*). However, statins elicited comparable effects on cholesterol synthesis irrespective of the examined tissue.

Table 3: FSR (fraction synthesis rate) of cholesterol in various parts of brain, results are expressed as mean \pm standard deviation, symbols ** and *** denote $p<0.01$ and $p<0.001$, respectively (vs. controls).

	Hippocampus	Basal ganglia	Frontal lobe	Spinal cord
Control group	0,048 \pm 0,0106	0,031 \pm 0,0075	0,056 \pm 0,0087	0,031 \pm 0,0087
Atorvastatin group	0,028 \pm 0,0066***	0,020 \pm 0,0034**	0,034 \pm 0,0059***	0,017 \pm 0,0053***
Simvastatin group	0,035 \pm 0,0076***	0,020 \pm 0,0061**	0,031 \pm 0,0073***	0,017 \pm 0,0045***
Alendronate group	0,035 \pm 0,0076***	0,030 \pm 0,0072	0,038 \pm 0,0077***	0,014 \pm 0,0084***

Figure 1: FSR (fraction synthesis rate) of cholesterol in brains of rats treated with simvastatin, atorvastatin or alendronate or fed high cholesterol diet as compared with control rats (Aqua).



Results are expressed as means \pm SEM, symbols ** and *** denote $p<0.01$ and $p<0.001$, respectively (vs. Aqua), symbols ## and ### denote $p<0.01$ and $p<0.001$, respectively (vs. respective lower doses).

However, none of the used treatments has manifested with a statistically significant effect on HMG-CoA reductase expression (*Figure 2* and *Table 2*).

Figure 2: HMG-CoA reductase protein in the rat brains.




7.3. Influence on cholinesterases

7.3.1. Effect on AChE and BuChE in blood

Comparison of data from control group with respective values from drug-treated animals did not show any statistically significant change in the activity of neither AChE nor BuChE (see *Figure 3*).


Figure 3: The effect of atorvastatin, simvastatin and alendronate on AChE activity in erythrocytes and BuChE activity in serum. Data are expressed as means + SEM.



7.3.2. Effect on AChE in the brain

AChE activity in the control (sham) group was compared with those measured in atorvastatin (50 mg/kg), simvastatin (50 mg/kg) and alendronate (3 mg/kg) groups in *Study I*. Seven-day administration of these agents had no statistically significant effect on AChE activity in the septum, basal ganglia or hippocampus. In contrast, simvastatin and alendronate significantly decreased AChE activity in the frontal cortex ($P < 0.05$, *Figure 4*).

Figure 4: The effect of atorvastatin, simvastatin and alendronate on AChE activity in brain (septum, basal ganglia, frontal cortex and hippocampus). Data are expressed as means + SEM. Symbol * denotes $p < 0.05$ (vs. sham).



In *Study III*, none of the used treatments (atorvastatin 10 or 20 mg/kg, simvastatin 10 or 20 mg/kg and alendronate 3 or 6 mg/kg) has expressed a statistically significant effect on acetylcholinesterase activity in brain hemisphere homogenate ($P = 0.18$) (see *Table 4*).

Table 4: HMG-CoA reductase protein content, acetylcholinesterase activity and amyloid beta (40) and (42) concentrations in the brains of rats treated with simvastatin, atorvastatin or alendronate or fed high cholesterol diet as compared with controls (Aqua). Data are expressed as means \pm SEM.

	Aqua	Si – 10	At – 10	Si – 20	At – 20	AI – 3	AI – 6	Chol
HMG-CoA reductase protein (% of Aqua)	100 ± 0.0	106.9 ± 2.7	115.5 ± 8.3	95.8 ± 4.8	101.7 ± 6.5	94.2 ± 2.4	103.3 ± 6.6	88.9 ± 5.8
AChE activity (μkat/kg)	316.5 ± 13.9	291.9 ± 19.3	304.9 ± 20.1	316.5 ± 19.1	251.6 ± 4.2	282.0 ± 29.0	259.2 ± 5.9	309.9 ± 27.8
Aβ (40) (pmol/g)	1.59 ± 0.09	1.66 ± 0.10	1.46 ± 0.06	1.49 ± 0.06	1.73 ± 0.23	1.68 ± 0.25	1.61 ± 0.15	1.44 ± 0.06
Aβ (42) (pmol/g)	0.34 ± 0.20	0.33 ± 0.01	0.30 ± 0.01	0.33 ± 0.02	0.35 ± 0.03	0.35 ± 0.20	0.35 ± 0.02	0.31 ± 0.01

7.4. Concentration of amyloid beta in the brain

None of the used treatments (atorvastatin 10 or 20 mg/kg, simvastatin 10 or 20 mg/kg and alendronate 3 or 6 mg/kg) has expressed a statistically significant effect on brain A β (40) ($P = 0.76$) and A β (42) ($P = 0.38$) concentrations (see *Table 4*).

8. DISCUSSION

8.1. Effects of statins

8.1.1. Biomarkers of cholesterol synthesis in the brain

Nearly all input of cholesterol into the CNS comes from in situ synthesis. Total cholesterol, 24S-hydroxycholesterol, lathosterol and 27-hydroxycholesterol are used as biomarkers for cholesterol metabolism monitoring. Cholesterol 24-hydroxylase (CYP46a1) in the brain is capable of converting cholesterol to 24S-hydroxycholesterol (cerebrosterol) which can cross the BBB, enters the plasma and hence can be used as a marker for cholesterol elimination (Dietschy and Turley 2001). Lathosterol is a cholesterol precursor and its ratio to cholesterol is believed to be a marker for cholesterol endogenous synthesis (Lutjohann et al. 2004).

However, to measure the absolute rate of sterol synthesis in vivo, quantitating the rates of incorporation of either ^2H or ^3H atom from [^2H] water or [^3H] water into cholesterol molecule, is recommended (Dietschy and Turley 2001). We have used (in *Study II and III*) $^2\text{H}_2\text{O}$ which is a safe, nonradioactive tracer and can be administered *per os*.

8.1.2. Influence on cholesterol synthesis

Statins are inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, which controls the key step in cholesterol biosynthesis. Among the widely prescribed statins, simvastatin (4.68), atorvastatin (4.06), lovastatin (4.27) and fluvastatin (3.24) are lipophilic, while pravastatin (-0.22) is regarded as a hydrophilic compound (in brackets: logarithm of the partition coefficient, Corsini et al. 1999, Schachter 2005).

Some experimental trials have investigated the effects of different statins on biomarkers of cholesterol synthesis and elimination (their results are summarized in *Table 3, Study IIa*). Generally speaking, statins have the ability to suppress cholesterol synthesis in the brain (i.e. lower lathosterol levels). Also in our studies, the administration of both simvastatin and atorvastatin suppressed cholesterol synthesis in the rat brain as evaluated by lathosterol (*Study III*) and cholesterol FSR (*Study IIa, Study III*). The decrease in cholesterol FSR and lathosterol/cholesterol ratio was dose-dependent, which confirms the relationship between statins and brain cholesterol synthesis. Concerning FSR, no statistically relevant difference between the corresponding simvastatin and atorvastatin groups was observed (i.e. the drugs had similar potency to produce a reduction of this parameter). This finding is in agreement with previous reports, where 3-week administration of simvastatin vs. pravastatin resulted in comparable effects with respect to lathosterol suppression (Lutjohann et al. 2004; Johnson-Anuna et al. 2005). Nonetheless, the rat brain was found to have a remarkable capacity to maintain cholesterol homeostasis in spite of considerable changes in FSR and also in the levels of circulating cholesterol, i.e. neither brain cholesterol FSR, nor reduction/elevation of plasma cholesterol had a significant effect on total brain cholesterol levels, a finding consonant with studies on guinea pigs (Lutjohann et al. 2004) or transgenic mice (Petanceska et al. 2002). This phenomenon may be explained either by suppressed cholesterol elimination (Lutjohann et al. 2004) or potentiated synthesis (manifested as significant up-regulation of HMG-CoA mRNA expression and activity in simvastatin-treated animals) in the brain tissue (Thelen et al. 2006, Franke et al. 2006). The latter may presumably represent a compensatory mechanism responsible for counteracting the inhibitory effect of high-dose statin treatment on brain cholesterol-synthesis (Thelen et al. 2006). Since we neither determined the marker of cholesterol elimination (24S-OH-cholesterol) nor HMG-CoA reductase activity, the stable levels of HMG-CoA reductase protein do not support the notion of its compensatory up-regulation and rather suggest suppressed cholesterol elimination. It also may be speculated that the failure to confirm significant compensatory elevations of HMG-CoA reductase protein in this study may be attributed to considerably (10-times) lower doses of drugs used. Nevertheless, this is the first study to measure total brain HMG-CoA reductase protein in statin-treated rats (*Study III*).

In this aspect it would be interesting to see if the effect on brain cholesterol metabolism is dependent on the grade of lipophilicity (which determines the drug's BBB transport). Some authors suggest that there is a slight difference between the effects of lipophilic (simvastatin) and hydrophilic (pravastatin) statins (in favor of the former) on brain cholesterol synthesis (Thelen et al. 2006). Moreover, Johnson-Anuna et al. demonstrate that although cholesterol levels fail to differ significantly between pravastatin and simvastatin-treated mice, the levels of statins in the cerebral cortex do reflect their hydrophobicity producing a greater reduction in cholesterol synthesis in simvastatin vs. pravastatin group (Johnson-Anuna et al. 2005). On the other hand, Lutjohann et al. suggest that brain cholesterol synthesis in guinea pigs is influenced by simvastatin as well as by pravastatin (Lutjohann et al. 2004). We examined the effects of simvastatin vs. atorvastatin using ten-times lower dose and somewhat longer duration of treatment (9 days vs. 3 days) than Thelen et al. (Thelen et al. 2006). To a large extent, the lack of variance between the two drugs used in the present study in terms of their effect on brain cholesterol synthesis may be attributed to a relatively small difference in lipophilicity (atorvastatin being less lipophilic than simvastatin), and/or the ability of both statins to cross the BBB, although the transport mechanism and permeation rate may differ (Tsuiji et al. 1993). The reason is the different form of the administered drug – atorvastatin, fluvastatin and pravastatin are normally administered in an active hydroxy-acid form (Malhotra and Goa, 2001), but simvastatin as an inactive lactone prodrug of the active hydroxy-acid form. HMG-CoA reductase inhibitors of lactone form are then able to simply

diffuse through the BBB, whereas those having an acid form are transported via a carrier-mediated transport system (Tsuji et al. 1993). This may help explain why atorvastatin is sometimes classified among hydrophilic compounds (Sparks et al. 2002) not crossing the BBB to any significant extent (Knopp 1999) in contrast to other studies, which expect considerable penetration of atorvastatin across the BBB (Kishi et al. 2008, Chen et al. 2008, Tanaka et al. 2007). As far as hydrophilic substances are concerned, the findings of their BBB permeation were supported also by microdialysis studies showing higher probability for active transport across the BBB for more drugs than expected. Hence, earlier assumptions that hydrophilic drugs have a slow (passive) equilibration across the BBB due to low permeability are largely questioned (de Lange et al. 2000). Therefore it seems that more lipophilic as well as more hydrophilic statins may directly lower brain cholesterol synthesis through local influence on brain tissue.

The effect of statins on brain cholesterol synthesis can also be considered indirect (via lowering plasma cholesterol). This point of view is advocated by Sparks et al. who hypothesize that reducing cholesterol in the blood be the safest way to decrease brain cholesterol and that direct inhibition of cholesterol synthesis within the CNS be ill-advised. By reducing cholesterol levels in the circulation, brain cholesterol will be lowered passively and safely (Sparks et al. 2002). This idea presupposes that brain and plasma cholesterols are exchangeable. Although the assumption of exchangeability has been challenged by some authors (for review see Dietschy and Turley 2004), others support the concept of low, but significant transport of cholesterol from the circulation into the brain (Lutjohann et al. 2004, Serougne et al. 1975). This discrepancy may be accounted for by different methods used for the measurement of cholesterol flux and by the rates of cholesterol synthesis being too low to be detected by current methods (Dietschy and Turley 2001). In the present experiment we have demonstrated, that both statins are able to lower brain cholesterol synthesis also without altering plasma cholesterol (see *Study IIa*), for which reason we adhere to the concept of local effect of statins on brain cholesterol synthesis. In the future, a direct measurement of the drugs in the brain tissue will bring valuable information.

8.1.3. Cholesterol synthesis in various parts of the CNS

The above mentioned studies have not investigated cholesterol and/or its synthesis in different parts of the animal brain. Some of them have examined the cerebral cortex (Johnson-Anua et al 2005; Petanceska et al 2001) the others whole brain homogenates (Lutjohann et al 2004; Thelen et al 2006 Mar). In our second study, we have taken samples from three parts of the rat brain (basal ganglia, hippocampus and frontal cortex) and the spinal cord. Cholesterol synthesis rate was the lowest in the spinal cord both in the simvastatin and atorvastatin groups (see *Study IIa*).

8.1.4. Influence on acetylcholinesterase and amyloid beta

One reason why statins and their influence on brain cholesterol metabolism are recently studied is that cholesterol was shown to be directly involved in the pathogenesis of Alzheimer's disease (AD). Cholesterol level in the brain and blood was found to positively correlate with the amount of A β , the characteristic AD protein (Kuo et al. 1998, Arvanitakis et al. 2000). Following statin treatment, some experimental studies documented decreased cell culture A β formation (Buxbaum et al. 2001, Fassbender et al. 2001), lower A β levels in the cerebrospinal fluid and brain homogenate of guinea pigs (Fassbender et al. 2001) and in the brain of transgenic mice with Alzheimer's amyloidosis (Petanceska et al. 2002). On the contrary, human trials using statins lack significant changes in this pathological protein either in plasma or cerebrospinal fluid (Hoglund et al. 2004, Hoglund et al. 2005, Sjogren et al. 2003). These discrepancies may, to a large extent, be due to pharmacological doses of the

drugs administered in humans, which may have proved insufficient to produce effects comparable to studies involving animals or cell cultures. In the present experimental study (*Study III*), 10-times lower doses (than those usually applied in experiments) were used. On one hand, this brought the given dosage closer to human medicine, but on the other hand, it may also account for our failure to observe significant alteration in brain A β levels.

Current therapeutic strategies for AD focus on inhibition of acetylcholinesterase (AChE), but the data concerning possible relationship between AChE and A β are very limited. Following addition of A β , Hu et al. documented elevated AChE expression in cultured cells (Hu et al. 2003). In our first study, we have also shown a decreased AChE activity in the brains of rats pretreated with simvastatin (50 mg/kg) (see *Study I*). A tendency towards lower AChE activity after statin treatment was observed also in the third experiment, although this trend failed to reach statistical significance (see *Study III*). A possible explanation for this inconsistency could lie in the fact that in the present study AChE activity was determined in the whole hemisphere and not selectively in the frontal cortex and also in the lower doses of statins used for treatment (10 and 20 mg/kg vs. 50 mg/kg) in *Study III*. However, we failed to demonstrate the relationships between A β and AChE activity and between A β and cholesterol. Despite a marked reduction in cholesterol synthesis, we did not observe any change in A β levels. It is possible that statins may affect cholinergic system in the brain under the terms of their pleiotropic effects without any relationship to cholesterol.

8.2 Effects of alendronate

As a molecular target of bisphosphonates in the cholesterol biosynthesis pathway, farnesyl diphosphate synthase (= isopentenyl transferase) was identified (Rezka and Rodan 2004). Concerning their potency to inhibit cholesterol biosynthesis, Canniga et al. demonstrated the ability of supratherapeutic doses of etidronate to lower human serum cholesterol and total lipid levels (Canigga et al. 1974). In addition, pamidronate induced a weak decrease in total cholesterol and shifted cholesterol from the low-density-lipoprotein to high-density-lipoprotein fraction in patients with Paget's bone disease (Montagnini et al. 2003). However, in ovariectomized rats, 3mg/kg b.wt. alendronate failed to produce a significant effect on blood cholesterol (Frolik et al. 1996). Our studies showed that when normal rats are used, this dose of alendronate is able to produce no (after 9 days, *Study IIb*) or only a weak (after 15 days, *Study III*) decrease in total plasma cholesterol.

As far as the brain is concerned, in our second study, we have found a significant decrease in cholesterol synthesis rate in the hippocampus, frontal lobe and spinal cord (*Table 1, Study IIb*), whereas the findings of our third study did not indicate the ability of alendronate to decrease tissue cholesterol or suppress its synthesis in the whole hemisphere (as seen in stable cholesterol, HMG-CoA reductase and cholesterol synthesis rate).

Unaware of a study describing an influence of bisphosphonates on cholinesterases, we hypothesized that cholesterol-lowering potency of these drugs might - like statins - prove beneficial in reduction of cholinesterases activities in blood and/or the brain. However, alendronate was not able to significantly decrease cholinesterase activity in serum (*Study I*).

Like simvastatin, alendronate significantly decreased the activity of AChE in the frontal cortex, a change not seen in other studied parts of the brain (*Study I*). A tendency towards lower AChE activity after alendronate treatment was observed also in the third experiment, although this trend failed to reach statistical significance (*Study III*). Moreover, no effect of alendronate on A β -40 or 42 was observed (*Study III*).

A possible explanation for this inconsistency could lie in the fact that instead of selective measurements in the frontal cortex, whole hemispheres were utilized in the present study. Direct determinations of alendronate bioavailability in the brain would bring valuable information to the discussion in the future.

8.3 Effects of high-cholesterol feeding

The exposure of rats to 2 % cholesterol diet, as realized in the present study, presented with a trend towards increased plasma cholesterol, whereas total brain cholesterol, lathosterol, brain cholesterol FSR as well as HMG-CoA protein remained unchanged as did A β and AChE activity. As to HMG-CoA reductase, similar results were obtained in its rat brain mRNA levels following 1% cholesterol diet (Jurevics et al. 2000). In contrast, higher amounts of cholesterol in the diet (1500 mg/day, which approximates 6-7 % cholesterol diet) led to markedly higher serum cholesterol and a significant decrease in brain cholesterol synthesis (as indicated by reduced brain lathosterol), but still did not affect total brain cholesterol in guinea pigs (Lutjohann et al. 2004). Notably, a diet containing 5 % cholesterol resulted in significantly increased levels of A β peptides in the CNS of transgenic mice (Refolo et al. 2000). These findings suggest that high-cholesterol diet may modify brain cholesterol synthesis and A β , but the effects are likely to be dose-dependent.

9. CONCLUSIONS

According to our best knowledge, the present experiments (*Study I and III*) are the first to show an influence of statins and alendronate on AChE activity in the rat brain. Moreover, our second study is the first experimental study comparing the influence of statins and alendronate on cholesterol synthesis in different parts of the rat brain using the incorporation of deuterium from deuterated water (*Study IIa and IIb*).

In our experiments, we confirmed the impact of statins on brain cholesterol synthesis using lathosterol, HMG-CoA reductase levels and the incorporation of deuterium from deuterated water (*Study III*). In comparison with prior studies we have used much lower doses of drugs, whereas the dose 20 mg/kg of statin for 15 days decreased plasma cholesterol and mimicked the effect described in humans.

The data concerning the effect of alendronate on cholesterol synthesis are inconsistent and need to be reevaluated using higher doses of alendronate.

Data from the third study question the relationship between A β , AChE and brain cholesterol synthesis (*Study III*) and that is why further experiments to examine the mechanism by which statins may reduce the risk of developing AD are needed.

Nowadays statins and alendronate are widely used and our results support the idea of their additional benefit. If the outcomes of our pilot experiments find support in other trials, they might have clinical implications in therapy of the Alzheimer's disease.

10. REFERENCES

- 1) Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Digwall C, De Strooper B, Dotti CG: Neuronal membrane cholesterol loss enhances amyloid peptide generation. *J Cell Biol* 2004;167:953-960.
- 2) Arvanitakis Z, Lucas JA, Graff-Radford NR. Correlation between serum cholesterol parameters and plasma amyloid beta protein. *Neurobiol Aging* 2000;21:96.
- 3) Bergmann CH: Diversification of gamma-secretase activity versus beta-secretase inhibition by cholesterol depletion. *Neurobiol Aging* 2000;21:278.
- 4) Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. *Can Journal Biochem Physiol* 1959;37:911-7.
- 5) Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate A β 1-42/1-40 ratio in vitro and in vivo. *Neuron* 1996;17:1005-13.
- 6) Buxbaum JD, Geoghagen NS, Friedhoff LT. Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. *J Alzheimers Dis* 2001;3(2):221-9.
- 7) Canigga A, Gennari C, Picci M. Disphosphonate (etidronate) lowers cholesterol and total lipid levels in the blood of humans. *Bioll Soc Ital Biol Sper* 1974;50:1416-1422.
- 8) Chen J, Zacharek A, Li A, Cui X, Roberts C, Lu M, Chopp M. Atrovastatin promotes presenilin-1 expression and Notch1 activity and increases neural progenitor cell proliferation after stroke. *Stroke* 2008;39(1):220-6.
- 9) Corsini A, Bellotta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. *Pharmacol Therap* 1999;84:413-28.
- 10) Darvesh S, Martin E, Walsh R, Rockwood K: Differential effects of lipid-lowering agents on human cholinesterases. *Clinical Biochemistry* 2004;37:42-49.
- 11) de Lange ECM, de Boer AG, Breimer DD. Methodological issues in microdialysis sampling for pharmacokinetic studies. *Advanced Drug Delivery Reviews* 2000;45:125-148.
- 12) Dietschy JM, Turley SD. Cholesterol metabolism in the brain. *Curr Opin Lipidol* 2001;12:105-12.
- 13) Dietschy JM, Turley SD. Cholesterol metabolism in the central nervous system during early development and in the mature animal. *Journal of Lipid Research* 2004;45:1375-1397.
- 14) Dietschy JM, Turley SD. Cholesterol metabolism in the central nervous system during early development and in the mature animal. *J Lipid Res* 2004;45:1375-1397.
- 15) Diraison F, Pachiaudi C, Beylot M. Measuring lipogenesis and cholesterol synthesis in humans with deuterated water: use of simple gas chromatographic/mass spectrometric techniques. *J Mass Spectrom* 1997;32:81-6.
- 16) Diraison F, Pachiaudi C, Beyot M. In vivo measurement of plasma cholesterol and fatty acid synthesis with deuterated water: determination of the average number of deuterium atoms incorporated. *Metabolism* 1996;45(7):817-821.
- 17) Eckert GP, Kirsch Ch, Mueller WE. Differential effects of lovastatin treatment on brain cholesterol levels in normal and ApoE-deficient mice. *NeuroReport* 2001;12(5):883-7.
- 18) Ellman GL, Courtney KD, Andres VL, Featherstone RM: A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol* 1961;7:88-95.

- 19) Fassbender K, Stroick M, Bertsch T, Ragoschke A, Kuehl S, Walter S et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. *Neurology* 2002;59:1257-8.
- 20) Fassbender K, Simons M, Bergmann C et al: Simvastatin strongly reduces levels of Alzheimers disease β -amyloid peptides A β 42 and A β 40 in vitro and in vivo. *PNAS* 2001;98:5856-61.
- 21) Franke C, Noldner M, Abdel-Kader R, Johnson-Anuna LN, Wood WG, Muller WE, Eckert GP. Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. *Neurobiology of Disease* 2007;25:438-45.
- 22) Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. Time-dependent changes in biochemical bole markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamxifen, estrogen and alendronate. *Bone* 1996;18:621-627.
- 23) Hoglund K, Syversen S, Lewczuk P, Wallin A, Wiltfang J, Blennow K. Statin treatment and a disease-specific pattern of β -amyloid peptides in Alzheimer's disease. *Exp Brain Res* 2005;164:205-14.
- 24) Hoglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blenow K. Plasma levels of beta-amyloid (1-40), beta-amyloid (1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. *Arch Neurol* 2004;61(3):333-7.
- 25) Hu W, Gray NW, Brimijoin S. Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. *J Neurochem* 2003;86(2):470-8.
- 26) Jirák J, Koukolík F: Alzheimerova nemoc. In: Demence, neurobiologie, klinický obraz, terapie. Jirák R, Koukolík F (eds), Galén, Praha, 2004, pp 124-147.
- 27) Johnson-Anuna LN, Eckert GP, Keller JH, Igbavboa U, Franke C, Fechner T et al. Chronic administration of stins alters multiple gene expression patterns in mouse cerebral cortex. *J Pharm Exp Ther* 2005;312:786-793.
- 28) Jurevics H, Hostettler J, Barrett C, Morell P, Toews AD. Diurnal and dietary-induced changes in cholesterol synthesis correlate with levels of mRNA of HMG-CoA reductase. *J Lipid Res* 2000;41:1048-53.
- 29) Kirsch Ch, Eckert GP, Mueller WE: Cholesterol attenuates the membrane perturbing properties of beta-amyloid peptides. *Amyloid* 2002;9:149-159.
- 30) Kishi T, Hirooka Y, Shimokawa H, Takeshita A, Sunagawa K. Atorvastatin reduces oxidative stress in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. *Clin Exp Hypertens* 2008;30(1):3-11.
- 31) Knopp RH. Drug treatment of lipid disorders. *N Engl J Med* 1999;341:498-511.
- 32) Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, Roher AE. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain A-beta 1-42 levels. *BBRC* 1998;252:711-5.
- 33) Liebisch G, Binder M, Schifferer R, Langmann T, Schulz B, Schmitz G. High throughput quantification of cholesterol and cholestryl ester by electrospray ionization tandem mass spectrometry (ESI-MS/MS). *Biochimica et Biophysica Acta* 2006;1761:121-8.
- 34) Locatelli S, Lutjohann D, Schmidt HH, Otto C, Beisiegel U, von Bergmann K: Reduction of plasma 24-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. *Arch Neurol* 2002;59:213-216.
- 35) Lutjohann D, Stroick M, Bertsch T, Kuhl S, Lindenthal B, Thelen K et al. High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. *Steroids* 2004;69(6):431-8.

- 36) Malhotra HS, Goa KL. Atorvastatin An updated review of its pharmacological properties and use in dyslipidaemia. *Drugs* 2001;61(12):1835-81.
- 37) Montagnini A, Gonnelli S, Cepollaro C et al. Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate. *Bone* 2003;32:15-19.
- 38) Muacevic-Kataneda D, Bradamante V, Reinec Z, Sucic Z, Poljicain T, Busljeta I, Metelko Z: Clinical study on the effect of simvastatin on butyrylcholinesterase activity. *Arzneimittelforschung* 2005;55:271-275.
- 39) Patočka J, Kuča K, Jun D: Acetylcholinesterase and butyrylcholinesterase – important enzymes of human body. Review article. *Acta Medica (Hradec Králové)* 2004;47:215-228.
- 40) Petanceska SS, DeRosa S, Olm V, Diaz N, Sharma A, Thomas-Bryant T et al. Statin therapy for Alzheimer's disease. Will it work? *J Mol Sci* 2002;16:155-61.
- 41) Rea TD, Britner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH. Statin use and the risk of incident dementia: the cardiovascular health study. *Arch Neurol* 2005;62(7):1047-51.
- 42) Refolo LM, Pappolla MA, Malester B, LaFrancois J, Bryant-Thomas T, Wang R et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. *Neurobiology of Disease* 2000;7:321-31.
- 43) Rezka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. *Mini Rev Med Chem* 2004;4:711-719.
- 44) Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. *Arch Neurol* 2002;59(2):223-7.
- 45) Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. *Pharm Res* 1994 Feb;11(2):305-11.
- 46) Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. *Fund Clin Pharm* 2004;19:17-125.
- 47) Serouge C, Lefevre C, Chevallier F. Cholesterol transfer between brain and plasma in the rat: A model for the turnover of cerebral cholesterol. *Exp Neurol* 1976;51:229-40.
- 48) Simons S, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. *Proc Natl Acad Sci* 95:6460-6464, 1998.
- 49) Sjogren M, Gustafsson K, Syversen S, Olsson A, Edman A, Davidsson P, Wallin A, Blennow K. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. *Dement Geriatr Cogn Disord* 2003;16(1):25-30.
- 50) Sparks DL, Connor DJ, Browne PJ, Lopez JE, Sabbagh MN. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advised to use one that crosses the blood-brain barrier. *J Nutr Health Aging* 2002;6(5):324-31.
- 51) Sparks DL: Intraneuronal β-amyloid immunoreactivity in the CNS. *Neurobiol Aging* 1996;17:291-9.
- 52) Tanaka N, Katayama Y, Katsumata T, Otori T, Nishiyama Y. Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats. *Brain Research* 2007;169:125-32.

- 53) Thelen KM, Rentsch KM, Gutteck U, Heverin M, Olin M, Andersson U et al. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not pravastatin. *J Pharmacol Exp Ther* 2006;316(3):1146-52.
- 54) Tsui A, Saheki A, Tamai I, Terasaki T. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the blood-brain barrier. *J Pharmacol Exp Ther* 1993;267(3):1085-90.
- 55) Wolozin B, Kellman W, Ruosseau G, Celestia G, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Arch Neurol.* 2000;57:1439-43.
- 56) Yang E, Diraison F, Beylot M, Brunengraber DZ, Samols MA, Anderson VE, Brunengraber H. Assay of low deuterium enrichment of water by isotropic exchange with [$\text{U}-^{13}\text{C}_3$] acetone and gas chromatography-mass spectrometry. *Analytical biochemistry* 1998;258:315-21.
- 57) Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. *Neuroepidemiology* 2004;23(1-2):94-8.
- 58) Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache cohort study. *Arch Gen Psychiatry* 2005;62(2):217-24.

11. LIST OF AUTHOR'S PUBLICATIONS

ORIGINAL ARTICLES

- 1) Cibiček N, **Cibičková L**, Kohout P, Žďánský P. The use of sucrose absorption test (SaLM) for detection of upper gastrointestinal tract mucosa affections in upper dyspepsia patients – a pilot study. *Acta Medica (Hradec Králové)* Suppl 2004; 47(1):23-28.
- 2) **Cibičková L**, Cibiček N, Žďánský P, Kohout P. The impairment of gastroduodenal mucosal barrier by coffee. *Acta Medica (Hradec Králové)* 2004; 47(4):275-8.
- 3) Soukup T, **Cibičková L**, Dahošová M, Tomš J, Bradna P, Hrnčíř Z. Protilátky proti tyreoglobulinu a tyreoperoxidáze u pacientů s revmatoidní artritidou se zaměřením na pacienty léčené anti TNF alfa. *Lék. zpr.* 2006; 51(4):293-298.
- 4) **Cibičková L**, Palička V, Cibiček N, Čermáková E, Mičuda S, Bartošová L, Jun D. Differential effects of statins and alendronate on cholinesterases in serum and brain of rats. *Physiol Res* 2007;56(6):765-770. **IF = 2.1**
- 5) **Cibičková L**, Soukup T, Čermáková E, Bradna P, Hrnčíř Zb. Kognitivní dysfunkce u pacientů se systémovým lupus erythematoses a antifosfolipidovými protilátkami. *Vnitřní Lékařství* 2007; 53(3):242-5.
- 6) **Cibickova L**, Hyspler R, Ticha A, Cibicek N, Palicka V, Cermakova E, Zadak Z. Cholesterol synthesis in central nervous system of rat is affected by simvastatin as well as by atorvastatin. *Pharmazie* 2008;63:819-22. **IF = 0.67**
- 7) **Cibickova L**, Palicka V, Hyspler R, Cibicek N, Cermakova E. Alendronate lowers cholesterol biosynthesis in the central nervous system of rats – a preliminary study. *Physiol Res* 2009;58(3). In print. **IF = 2.1**
- 8) **Cibickova L**, Hyspler R, Micuda S, Cibicek N, Zivna H, Jun D, Ticha A, Palicka V: The influence of simvastatin, atorvastatin, and high cholesterol diet on acetylcholinesterase activity, amyloid beta and cholesterol synthesis in rat brain. *Steroids* 2009;74:13-19. In print. **IF = 2.4**

REVIEWS

- 1) **Cibičková L**, Palička V. Alzheimerova choroba, cholesterol a apolipoprotein E – nové souvislosti. *Klinická biochemie a metabolismus* 2005; 13(24):127-130.
- 2) **Cibičková L**, Palička V. Galantamin v terapii Alzheimerovy demence. *Česká geriatrická revue* 2005;3(2):29-34.
- 3) **Cibičková L**, Soukup T, Cibiček N, Chládek J. Nitric oxide and systemic sclerosis. *Acta Medica (Hradec Králové)* 2006; 49(4):245-246. (Brief communication)
- 4) **Cibičková L**. Neuroprotektivní účinky statinů u Alzheimerovy demence. *Farmakoterapie* 2006; 6:593-595.
- 5) **Cibičková L**, Palička V. Existuje vztah mezi statiny a cholinergním systémem? *Klinická farmakologie a farmacie* 2006; 20(1):38-40.
- 6) **Cibičková L**, Cibiček N. Budou mít statiny a bisfosfonáty společné indikace? *Farmakoterapie* 2007;6:564-5.
- 7) **Cibičková L**. Působení statinů na metabolizmus cholesterolu v centrálním nervovém systému. *DMEV* 2008;3(11):145-7.

CASE REPORTS

- 1) **Cibičková L**, Soukup T., Bradna P. , Baštecká D., Šimáková E. , Hrnčíř Z. Asociace revmatoidní artritidy a Castlemanovy choroby. *Česká revmatologie* 2005; 3:106-109.
- 2) **Cibičková L**, Soukup T, Vališ M, Jakubcová O, Taláb R, Bradna P, Hrnčíř Z. Asociace primární idiopatické polymyozitidy a roztroušené sklerózy mozkomíšní. *Česká a slovenská neurologie a neurochirurgie* 2006; 69(2):134-136. **IF=0.07**

- 3) **Cibičková L**, Horacek J, Prasil P, Slovacek L, Kohout A, Cerovsky V, Hobza V. Cerebral toxoplasmosis in an allogeneic peripheral stem cell transplant recipient. *Transplant Infectious Disease* 2007;9:332-5.

ABSTRACTS

- 1) **Cibičková L**, Soukup T., Prixová M. Asociace diabetes mellitus typu LADA a Castlemanovy choroby. DMEV Supplementum 2005; 1:15.
- 2) **Cibičková L**, Soukup T., Jakubcová O. Společné rysy idiopatické polymyozitidy a roztroušené sklerózy - kazuistika. *Vnitř Lék* 2005; 51(5):624-5. (abstract, in Czech)
- 3) Tošovský M., Bláha V., Bláha M., **Cibičková L**, Prixová M. Použití extrakorporální plazmaferézy v léčbě těžké hyperlipidémie a u pacienta s primární idiopatickou polymyositidou. *Klinická výživa u postižení ledvin, metabolismus vápníku, akutní metabolická péče* 2005; 107-108.
- 4) **Cibičková L**, Soukup T. Cognitive dysfunction in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. *Annals of the Rheumatic Diseases* 2006; 65(2):195. **IF = 7,0**
- 5) Soukup T, **Cibičková L**, Malířová E, Dostál P, Maňák J, Bradna P, Hrnčíř Z. Význam stanovení sérové hladiny procalcitoninu ve včasné diferenciální diagnostice septických stavů a aktivních forem difuzních nemocí pojiva. *Česká revmatologie* 2006; 14(1):40.
- 6) Soukup T, **Cibičková L**, Tomš J., Malířová E., Bradna P., Hrnčíř Z. Procalcitonin as an indicator of infection in patients with connective tissue diseases. *Annals of Rheumatic Diseases* 2006; 65(2):S649. **IF = 7,0**
- 7) **Cibičková L**, Palička V. Efekt podávání statinů a alendronátu na cholinesterázy v séru a mozku potkanů. Nové přístupy v diagnostice a léčbě akutních stavů v gerontologii 2005; 44-45, vydalo Medica Publishing & Consulting s.r.o., Brno.
- 8) **Cibičková L**, Palička V, Hyšpler R. Vliv statinů na aktivitu acetylcholinesterázy a syntézu cholesterolu v mozku potkanů. *Vnitř Lék* 2007;53(5):602.
- 9) **Cibičková L**, Hyšpler R, Palička V, Čermáková E., Cibiček N. Cholesterol synthesis in central nervous system of rat is affected by simvastatin as well as by atorvastatin. *Clinical Nutrition* 2007;2 (Suppl 2):17 **IF= 2,47**

PRESENTATIONS IN SEMINARS AND CONFERENCES

- 1) **Cibičková L**, Soukup T., Prixová M. Asociace diabetes mellitus typu LADA a Castlemanovy choroby. DMEV Supplementum 2005; 1:15. (poster)
- 2) **Cibičková L**, Soukup T., Jakubcová O. Společné rysy idiopatické polymyozitidy a roztroušené sklerózy. *Vnitř Lék* 2005; 51(5):624-5. (oral presentation)
- 3) **Cibičková L**, Soukup T. Cognitive dysfunction in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. *Annals of the Rheumatic Diseases* 2006; 65(2):S195. **IF = 7,0** (poster)
- 4) Soukup T, **Cibičková L**, Tomš J., Malířová E., Bradna P., Hrnčíř Z. Procalcitonin as an indicator of infection in patients with connective tissue diseases. *Annals of Rheumatic Diseases* 2006; 65(2):S649. **IF = 7,0** (poster)
- 5) **Cibičková L**, Palička V. Efekt podávání statinů a alendronátu na cholinesterázy v séru a mozku potkanů. Nové přístupy v diagnostice a léčbě akutních stavů v gerontologii 2005; 44-45. (poster)
- 6) **Cibičková L**, Palička V, Hyšpler R. Vliv statinů na aktivitu acetylcholinesterázy a syntézu cholesterolu v mozku potkanů. *Vnitř Lék* 2007;53(5):602. (oral presentation)
- 7) **Cibičková L**, Hyšpler R, Palička V, Čermáková E., Cibiček N. Cholesterol synthesis in central nervous system of rat is affected by simvastatin as well as by atorvastatin. *Clinical Nutrition* 2007;2 (Suppl 2):17 (oral presentation)